Headlines about Alnylam Pharmaceuticals (NASDAQ:ALNY) have been trending somewhat positive on Saturday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alnylam Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.5199364314649 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news articles that may have impacted Accern’s rankings:
- Alnylam Pharmaceuticals, Inc. (ALNY) Rating Reiterated by Credit Suisse Group (americanbankingnews.com)
- Alnylam (ALNY) Q2 Loss Narrower than Expected, Sales Miss – Nasdaq (nasdaq.com)
- There Are Mixed Technical Signals in Alnylam Pharmaceuticals, Inc. (ALNY) – StockNewsGazette (stocknewsgazette.com)
- EARNINGS SUMMARY: Details of Alnylam Pharmaceuticals Inc. Q2 Earnings Report (rttnews.com)
- ALNY Beats EPS Loss Estimates By $0.10. Misses On Revenues. (investorsbuz.com)
Several analysts have commented on the stock. Jefferies Group LLC restated a “buy” rating and set a $102.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday, June 22nd. Chardan Capital restated a “buy” rating and set a $131.00 price objective (up from $110.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, July 10th. Needham & Company LLC restated a “buy” rating and set a $98.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, July 10th. Credit Suisse Group lifted their price objective on shares of Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the company an “outperform” rating in a research note on Tuesday, June 27th. Finally, J P Morgan Chase & Co restated a “hold” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, June 26th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $81.74.
Alnylam Pharmaceuticals (ALNY) traded up 3.00% during trading on Friday, reaching $78.22. 847,539 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $80.94 and a 200 day moving average price of $61.92. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $86.92. The firm’s market capitalization is $7.18 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.22) by $0.12. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The firm had revenue of $15.93 million for the quarter, compared to analysts’ expectations of $23.86 million. During the same quarter in the previous year, the firm posted ($1.05) EPS. The firm’s revenue for the quarter was up 82.9% compared to the same quarter last year. Equities research analysts forecast that Alnylam Pharmaceuticals will post ($5.23) earnings per share for the current fiscal year.
In related news, major shareholder Sanofi purchased 297,501 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, May 31st. The shares were purchased at an average cost of $71.87 per share, with a total value of $21,381,396.87. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Akshay Vaishnaw sold 43,750 shares of the business’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $65.00, for a total value of $2,843,750.00. Following the transaction, the senior vice president now directly owns 43,047 shares in the company, valued at $2,798,055. The disclosure for this sale can be found here. Insiders have sold a total of 64,125 shares of company stock worth $4,325,000 over the last three months. 4.30% of the stock is currently owned by corporate insiders.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.